Short Interest in Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) Declines By 20.1%

Key Points

• Short interest in Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) decreased by 20.1% from July to August, with current short interest at 65,700 shares.
• Institutional investors currently own 30.11% of Brainsway stock, with several firms like Two Sigma Investments and Cubist Systematic Strategies recently increasing their stakes.
• The recent quarterly earnings reported an EPS of $0.10, beating expectations, and the stock has received upgraded ratings from brokers including Northland Securities and HC Wainwright.

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY - Get Free Report) saw a significant decline in short interest in August. As of August 15th, there was short interest totaling 65,700 shares, a decline of 20.1% from the July 31st total of 82,200 shares. Based on an average daily trading volume, of 57,100 shares, the short-interest ratio is presently 1.2 days. Based on an average daily trading volume, of 57,100 shares, the short-interest ratio is presently 1.2 days.

Brainsway Trading Up 0.4%

Shares of BWAY stock traded up $0.07 during trading hours on Friday, reaching $15.77. 16,204 shares of the company's stock were exchanged, compared to its average volume of 78,197. The stock's 50 day moving average is $13.48 and its 200-day moving average is $11.18. The company has a market cap of $298.08 million, a price-to-earnings ratio of 60.66 and a beta of 1.34. Brainsway has a fifty-two week low of $7.84 and a fifty-two week high of $16.25.

Brainsway (NASDAQ:BWAY - Get Free Report) last issued its quarterly earnings results on Wednesday, August 13th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.07 by $0.03. The business had revenue of $12.63 million for the quarter, compared to the consensus estimate of $12.34 million. Brainsway had a return on equity of 8.97% and a net margin of 11.60%. Brainsway has set its FY 2025 guidance at EPS. Equities analysts anticipate that Brainsway will post 0.08 EPS for the current year.

Analyst Upgrades and Downgrades

BWAY has been the subject of a number of recent research reports. Wall Street Zen raised shares of Brainsway from a "hold" rating to a "buy" rating in a research note on Sunday, August 17th. HC Wainwright reissued a "buy" rating and issued a $17.00 price objective on shares of Brainsway in a research note on Monday, August 25th. Finally, Northland Securities boosted their price objective on shares of Brainsway from $15.00 to $19.00 and gave the stock an "outperform" rating in a research note on Thursday, August 14th. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $18.00.

Hedge Funds Weigh In On Brainsway

A number of large investors have recently made changes to their positions in BWAY. Valor Management LLC acquired a new position in shares of Brainsway during the fourth quarter worth $19,838,000. Eagle Global Advisors LLC acquired a new position in shares of Brainsway in the 1st quarter valued at $590,000. Two Sigma Advisers LP increased its position in shares of Brainsway by 32.6% in the 4th quarter. Two Sigma Advisers LP now owns 60,600 shares of the company's stock valued at $571,000 after acquiring an additional 14,900 shares during the period. Trexquant Investment LP acquired a new position in shares of Brainsway in the 1st quarter valued at $129,000. Finally, ARK Investment Management LLC increased its position in shares of Brainsway by 7.3% in the 1st quarter. ARK Investment Management LLC now owns 188,328 shares of the company's stock valued at $1,783,000 after acquiring an additional 12,740 shares during the period. 30.11% of the stock is owned by institutional investors and hedge funds.

Brainsway Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.